Results 61 to 70 of about 16,802 (177)

Type I and II Interferon Signalling Characterizes the Transcriptional Landscape of Sweet Syndrome

Experimental Dermatology, Volume 35, Issue 7, July 2026.
ABSTRACT Sweet syndrome (SS) is an autoinflammatory neutrophilic dermatosis characterized by abrupt‐onset inflammatory skin lesions and systemic symptoms, yet its molecular pathogenesis remains incompletely defined. To delineate disease‐specific inflammatory programmes, we performed NanoString‐based transcriptomic analysis of SS skin lesions and ...
Laura Calabrese, Chiara Moltrasio, Maurizio Romagnuolo, Pia‐Charlotte Stadler, Zeno Fiocco, Matthias Neulinger‐Muñoz, Rui Aoki, Martina D'Onghia, Pietro Rubegni, Katrin Kerl, Takashi K. Satoh, Angelo V. Marzano, Lars E. French   +12 more
wiley   +1 more source

Integrative Multi‐Omics Analysis Elucidates the Progressive Disease Landscape and Reveals Dynamic Protein Biomarkers for MASLD Surveillance

The FASEB Journal, Volume 40, Issue 12, 30 June 2026.
Integrated transcriptomic, single‐cell, pseudotime, cell–cell communication, human tissue, and in vivo analyses define a dynamic four‐gene axis across the MASLD continuum. Progressive CYP2C19 downregulation and AKR1B10, COL1A2, and SPP1 upregulation link metabolic dysfunction to disease progression, while AKR1B10 knockdown or CYP2C19 overexpression ...
Kejun Liu, Bozhi Zhang, Yezhen Tang, Zhenyao Tan, Yang Bu, Yongxue Lv   +5 more
wiley   +1 more source

Mesenteric Adipose Tissue as a Modulator of Intestinal Inflammation: Mechanistic Insights and Model Systems in Crohn's Disease

European Journal of Immunology, Volume 56, Issue 6, June 2026.
This review explores how mesenteric adipose tissue, particularly creeping fat, contributes to intestinal inflammation through dysregulated adipokine signalling. We explore how metabolic stress alters immune‐adipose interactions and promotes disease progression.
Toka Omar, Carl Weidinger, Britta Siegmund   +2 more
wiley   +1 more source

Recent developments in lipodystrophy

Current Opinion in Lipidology, 2019
Purpose of review Lipodystrophy syndromes have an estimated prevalence of 1.3–4.7 cases per million and as with other rare diseases conducting research can be challenging. The present review highlights recently published work that has provided insights into the field of non-HIV--associated lipodystrophy syndromes.
Melvin, Audrey, Savage, David, Stears, Anna   +2 more
openaire   +3 more sources

Body composition and lipodystrophy in prepubertal HIV-infected children

Brazilian Journal of Infectious Diseases, 2013
Objective: To identify lipodystrophy in prepubertal HIV-infected children using anthropometric parameters and body composition assessment. Methods: Cross-sectional study including 40 prepubertal HIV-infected children of both genders seen at the Care ...
Cecilia Zanin Palchetti, Rose Vega Patin, Aída de Fátima Thomé Barbosa Gouvêa, Vera Lúcia Szejnfeld, Regina Célia de Menezes Succi, Fernanda Luisa Ceragioli Oliveira   +5 more
doaj   +1 more source

Generalized Lipodystrophy [PDF]

Archives of Disease in Childhood, 1971
M, SEIP, O, TRYGSTAD
openaire   +5 more sources

A series of genetically confirmed congenital lipodystrophy and diabetes in adult southern Indian patients

Scientific Reports
In this study, we analysed the mutation spectrum in subjects with suspected lipodystrophy using a targeted Next-generation sequencing (NGS) approach. Subjects with suspected lipodystrophy were for screened six genes (AGPAT2, BSCL2, LMNA, PPARG, ZMPSTE24,
Remya Rajan, Aaron Chapla, Jabasteen Johnson, Deny Varghese, H. S. Asha, Felix Jebasingh, Nitin Kapoor, Thomas V. Paul, Nihal Thomas   +8 more
doaj   +1 more source

Treatment of facial lipodystrophy induced by a biologic agent (IPD-1): a literature review [PDF]

Einstein (São Paulo)
Agents that inhibit programmed cell death (IPD-1) in T lymphocytes are indicated for patients with advanced cancer. However, some individuals may develop endocrinological conditions, such as diabetes, thyroid dysfunction, and lipodystrophy, after ...
Henri Friedhofer, Cristina Pires Camargo, Leandro Hirokazu Oshiro, Daniel de Almeida Rocha Valente, Rolf Gemperli   +4 more
doaj   +1 more source

Prevalence of lipodystrophy associated with human recombinant insulin

Journal of Mazandaran University of Medical Sciences, 2008
Background and Purpose: Lipodystrophy is potentially a clinical adverse effect, associated with insulin therapy and is believed that usage of human recombinant insulin’s is associated with decreasing prevalence of Lipodystrophy.
S. Akbarzadeh, O. Akha, Z. Hajheydari, Z. Kashi   +3 more
doaj  

Generalized Lipodystrophy [PDF]

Journal of the Royal Society of Medicine, 1984
S, Lieberman-Leigh, J A, Davis
openaire   +2 more sources